Publications by authors named "E Tabouret"

Claim this Profile
F
From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.
Nelleke Tolboom, Nathalie L Albert, Arthur J A T Braat, Tom J Snijders, Emeline Tabouret

J Nucl Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Emeline Tabouret

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation].
Jean Levasseur, Emeline Tabouret

Bull Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Emeline Tabouret

J Neurooncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. 2020, , 1935.
Emeline Tabouret, Herui Wang, Niranjana Amin, Jinkyu Jung, Romain Appay

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis